CVS Targets Affordable GLP-1 Access With New Eli Lilly Deal
CVS Health beats Q2 earnings expectations and hikes FY26 guidance, but shares fall on profit-taking. Get the full financial breakdown.
CVS made more money than people expected and partnered with Eli Lilly to make expensive weight-loss medicines cheaper for more people. When a big company does well and helps customers, that's usually something to notice—though right now investors are taking profits and selling anyway.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.